Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions.

Exhibit 10.21

COMMAND NO: DAMD17-04-0024

LICENSE NO.:

LICENSE AGREEMENT

THIS LICENSE AGREEMENT (“Agreement”), effective as of the “Signature Date” (as defined below), is made by and between: U.S. Army Medical Research Institute of Infectious Diseases (“Licensor”), a subordinate laboratory of the United States Army Medical Research and Materiel Command, having a place of business at 504 Scott Street, Fort Detrick, Maryland 21702-5012; and VaxGen Inc. (“Licensee”) a Delaware corporation, having a principal place of business at 1000 Marina Boulevard, Brisbane, California 94005-1841.

ARTICLE I

BACKGROUND

1.1 The United States of America is the owner by assignment or otherwise of the entire right, title and interest to inventions more particularly described and claimed in each of the patents and patent applications, including provisional applications, as well as all rights corresponding thereto, listed on Schedule 2.17 – A Existing Patents (collectively, the “Existing Patents”).

1.2 Under the authority of 15 United States Code 3701 et seq., 35 United States Code Section 200-210, and 37 Code of Federal Regulations, Chapter IV (together with any amendments and the underlying rules and regulations now or hereafter promulgated collectively, the “Federal Technology Transfer Act” or the “FTTA”), Licensor has custody of inventions described and claimed in, and the right to issue licenses under, the Existing Patents.

1.3 Licensor desires that the inventions described and claimed in the Existing Patents be brought to the “Point of Practical Applications” (as defined below) in the shortest possible time and made available to the public, thereby serving the public interest and broadening the potential supply base for Licensor and other U.S. government agencies.

1.4 Licensee desires to obtain an exclusive license to U.S. patent 6,387,665, Method of Making a Vaccine for Anthrax, and an exclusive field of use license to U.S. patent 6,316,006, Asporagenic B. anthracis Expression System, for the purpose of developing and commercializing a vaccine against B. antracis. Licensee understands and acknowledges that any and all inventions and technology related to or arising out of the Existing Patents would now and hereafter be subject to and governed by the terms and conditions of this Agreement.

NOW THEREFORE, in consideration of the premises noted above, including the above-cited statutory authority, and the mutual promises, covenants, duties and obligations hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Licensor and Licensee, intending to be lawfully bound, do agree as follows:

ARTICLE II

DEFINITIONS

The terms defined in this Article II shall have the meanings set forth below throughout this Agreement.

2.1	“Additional Information” shall have the meaning set forth in Article V hereof.

2.2 “Affiliate(s)” means any corporation or other legal entity that controls, is controlled by, or is under common control with Licensee. For purposes of this definition, “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”), means, whether de jure or de factor, the ownership, directly or indirectly, of more than fifty percent (50%) of the outstanding equity securities of a corporation which are entitled to vote in the election of its Board of Directors or more than fifty percent (50%) interest in the net assets or profits of any entity which is not a corporation. For the purposes of this definition, Affiliates shall include those Affiliates that are, or will become, Sublicensees under this Agreement and Licensee shall initially and continuously identify, designate and update its relationship with each Sublicensee and each Affiliate on Schedule 2.2 (Affiliates & Sublicensees) attached hereto and made a material part hereof, amended or supplemented from time to time after notice and with approval of Licensor as contemplated hereunder.

2.3	“Agreement” means this agreement.

2.4 “Bankrupt” means when any Person shall (a) apply for or consent to the appointment of, or the taking of possession by, a receiver, custodian, trustee or liquidator of any of the assets of same; (b) admit in writing an inability, or be generally unable, to pay debts as they become due; (c) make a general assignment for the benefit of creditors; (d) commence a voluntary case under the federal bankruptcy laws (now or hereafter in effect); (e) be adjudicated a bankrupt or insolvent; (f) file a petition seeking to take advantage of any other law providing for the relief of debtors; (g) acquiesce to, or fail to have dismissed, within thirty (30) days, any petition filed in any involuntary case under such bankruptcy laws; or (h) take any action for the purpose of effecting any of the foregoing.

2.5	“Board” means the Board of Directors of Licensee or an Affiliate, as it may apply.

2.6 “Confidential Information” shall mean (a) any proprietary or confidential information or material in tangible form disclosed in accordance with this Agreement that is marked as “Confidential,” “Proprietary” or the like at the time it is delivered to the receiving party, (b) proprietary or confidential information disclosed orally hereunder which is identified as confidential or proprietary when disclosed and such disclosure of confidential information is confirmed in writing within thirty (30) days by the disclosing party, or (c) Trade Secrets of

Licensor regardless of whether or not so marked or identified. For purposes of this Agreement, “Confidential Information” shall not include information that can be established by the receiving party by competent proof that such information:

(i) was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure;

(ii) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party;

(iii) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving party in breach of this Agreement;

(iv) was subsequently lawfully disclosed to the receiving party by a person other than a party hereto; or

(v) was lawfully developed independently by the receiving party without misappropriating confidential information from a third party.

2.7 “Development Plan” means the comprehensive plan and related exhibits, schedules and agreements prepared for the sole benefit of Licensor and undertaken by Licensee to commercialize the Licensed Patent Technology substantially in the form of Schedule 2.7 (Development Plan) attached hereto and made a material part hereof, amended or supplemented from time to time after notice and with approval of Licensor.

2.8 “End User” means any Person with the right to use Licensed Products for his/her own personal use or in the regular conduct of its own business and not for licensing to other Persons.

2.9	“EU” means European Union.

2.10	“Event of Default” shall have the meaning used in Article XI.

2.11	“Existing Patents” shall have the meaning used in Article I.

2.12	“FTTA” shall have the meaning used in Article I.

2.13	“Government” means the federal government of the United States of America.

2.14 “Improvement” means any revision, translation, abridgement, condensation, expansion, modification or any other form in which an invention may be recast, transformed or adapted, provided any such modification would infringe on one or more valid claims of a patent or pending patent application of such invention. For purposes hereof, an Improvement shall also include any enhancement or derivative work, product, device or invention that incorporates a preexisting work, product, device or invention.

2.15 “Intellectual Property Rights” means, solely with respect to the Licensor, any or all of the following, in any and all jurisdictions throughout the world, and all rights in, arising out of, or associated with: (a) all patents (including Existing Patents and the Licensed Patent Technology) and applications therefore, including provisional applications, and all reissues, divisions, renewals, extensions, reexaminations, continuations and continuations-in-part thereof (“Patents”); (b) all rights (other than Patents) in inventions (whether patentable or not), invention disclosures, formulations, pre-clinical data, clinical data, laboratory data, manufacturing processes, processes, methods, techniques, trade secrets, proprietary information, know-how, technology and technical data (“Trade Secrets”); (c) all copyrights, copyright registrations and applications therefore and all other rights corresponding thereto (“Copyrights”); (d) all mask works, mask work registrations and applications therefore; (e) all industrial designs and any registrations and applications therefore; (f) any other rights in databases and data collections; (g) any other rights in computer software including all source code, object code, firmware, development tools, files, records and data, and all media on which any of the foregoing is recorded; (h) all know-how and show-how, techniques, design rules, ideas, concepts, methods, algorithms, formulae, discoveries, compositions, routines, files, works of authorship, processes, prototypes, devices and hardware whether or not protectible by Patents, Copyrights or Trade Secrets, and (i) any similar, corresponding or equivalent rights or Improvement in which Licensor has property rights to any and all of the foregoing and any other intellectual property or proprietary rights, whether or not registrable; including, without limitation, any and all trademarks, trade names, domain names, logos and service marks and any similar indications of origin or branding expressly reserved for use by or identified with Licensor, unless otherwise stated.

2.16 “Licensed Field of Use” means applications or uses for the Licensed Patent Technology for human use as a vaccine for the prevention or treatment of anthrax infection.

2.17 “Licensed Patent Technology” means all of Licensor’s rights in but limited to (a) the Existing Patents listed on Schedule 2.17 – A (Existing Patents) attached hereto and made a material part hereof, including any extensions, reissues and reexaminations thereof, and (b) any and all additional patents and patent applications and ancillary Intellectual Property Rights identified and listed with the approval of Licensor on Schedule 2.17 – B (Additional Patents and Patent Applications[D1]) attached hereto and made a material part hereof, including any extensions, reissues and reexaminations thereof. Licensed Patent Technology shall include any and all divisions, renewals, continuations, continuations in part and substitutions related to the patents and patent applications referenced in subsections (a) and (b) of this Section; all foreign patent applications corresponding to the foregoing applications; and all U.S. and foreign patents issuing on any of the foregoing applications, including extensions, reissues, and reexaminations. Schedule 1.7 – A and B may be supplemented from time to time as deemed necessary or advisable in the sole discretion of Licensor.

2.18 “Licensed Product(s)” means any and all products, methods, inventions or devices of any kind and the information related thereto which either (a) fall within or are covered by the scope of one or more Valid Claims of the Licensed Patent Technology; (b) are produced by the practice of a product, method, invention, device or process that is within the scope of one or more Valid Claims of the Licensed Patent Technology; or (c) are produced by, derived or compiled from products, methods, inventions, devices, substances, techniques, processes, systems, formulations,

or designs described in the Licensed Patent Technology, in the country of use, manufacture or sale by Licensee or its Affiliate(s) and Sublicensees.

2.19	“Licensed Territory” means worldwide.

2.20 “Licensee” means VaxGen, Inc., 1000 Marina Boulevard, Brisbane, California 94005-1841.

2.21	“License Fee(s)” has the meaning set forth in Article IV.

2.22 “Licensor: means U.S. Army Medical Research Institute of Infectious Diseases, a subordinate laboratory of the U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

2.23 “Licensor’s Director” means the director of Licensor, or if such post is vacant or has been eliminated, then the representative within or overseeing Licensor who is authorized to approve, and execute on behalf of Licensor, this Agreement.

2.24 “Licensor’s Representative” means the Office of Research and Technology Application, U.S. Army Medical Research and Materiel Command, Staff Judge Advocate (MRMC-JA), 504 Scott Street, Fort Detrick, Maryland 21702-5012, Attn: USAMRMC ORTA.

2.25 “Net Sales” means the actual gross amount billed, invoiced, charged or received on sales or transfers of any Licensed Products by Licensee, its Affiliates and Sublicensees to any and all Unaffiliated Person(s), or in the event of disposal of any Licensed Products other than as scrap prior to shipment from its place of manufacture or predisposal storage, or other than by sales, the amount billed, invoiced, charged or received on sales or transfers for a like quantity and quality of Licensed Products to Unaffiliated Persons on or about the time of such disposal, less:

(a) trade, cash and quantity discounts, including charge backs, rebates, premiums, allowances and any other deduction actually granted to the Unaffiliated Person (not to exceed the original billing);

(b) sales and excise taxes and duties and any other governmental charges imposed upon the importation, use or sale of the Licensed Products actually charged to the Unaffiliated Person;

(d) amounts repaid or credited (not to exceed the original billing) by reason of rejections, defects, outdating, price differences, recalls or returns, or because of retroactive price reductions, or due to governmental laws or regulations requiring rebates actually granted to the Unaffiliated Person; and

(e)

actual charges for bad debts.

For purposes of calculating Net Sales for any reporting period, any and all deductions used in calculating Net Sales are allowable only to the extent that they have already been included in the amounts billed, invoiced, charged or received or granted on the sales or transfers of Licensed Products by Licensee or its Affiliates and Sublicensees to Unaffiliated Persons in bona fide arms’ length transactions. Calculation of Net Sales shall be in accordance with generally accepted accounting principles. Sales or transfers of Licensed Product between or among Licensee and its Affiliates(s) or Sublicensees shall be excluded from the computations of Net Sales except where such Affiliate(s) or Sublicensees are End Users, but Net Sales shall include the subsequent final sales or transfers to Unaffiliated Persons by such Affiliate(s) or Sublicensees (if not End Users).

In the case of a Licensed Product utilizing a combination of properties other than Licensed Product properties, solely for purposes of determining what percentage of License Fees are owed to Licensor hereunder Net Sales shall be multiplied by A/A+B, where A is the invoice price of the Licensed Product sold separately and B is the invoice price of the active properties in the combination of properties other than Licensed Product properties. If the invoice price of the Licensed Product and/or of the active properties in the combination is (are) not available and the parties are unable to agree on an alternative arrangement, then in lieu and stead of the fraction noted above Net Sales shall be multiplied by X/Y, where X is one (1) and Y is the total number of active properties included in the combination.

2.26	“Pass Through Royalty” shall have the meaning used in Article IV.

2.27 “Person” means any natural person or entity other than Licensee, its Affiliate(s) or Sublicensees including, without limitation, any individual, partnership (whether general or limited), limited liability company, corporation, trust, estate, association, nominee, firm, unincorporated organization or a government or agency or political subdivision thereof.

2.28 “Point of Practical Application” means to manufacture, practice, or to operate inventions, described and claimed in the Licensed Patent Technology, under such conditions as to establish that the inventions are being utilized and that their benefits are, to the extent permitted by law or Government regulations, available to the public on reasonable terms within six (6) years of the Signature Date, and to continue during the term of this Agreement to make the benefits of the inventions reasonably accessible to the public, consistent with sound and reasonable business practices and judgment. If Licensee believes that it will be unable to make such product available to the public within such time frame, it shall give notice to Licensor by way of a detailed explanation specifying the reasons therefore. Licensee may amend the time period at any time with the written consent of Licensor. Unless Licensee has failed to perform its duties and obligations under this Agreement, Licensor shall not unreasonably withhold approval of any request by Licensee to extend the time period if such request is supported by a reasonable showing that Licensee has in accord with the Development Plan taken diligent steps consistent with sound and reasonable business practices and judgment to commercialize the Licensed Patent Technology, taking into account any change in circumstances, scientific developments, or other factors considered by the parties relevant for adopting a new time frame.

2.29	“Point of Practical Application Reports” shall have the meaning set forth in Article V.

2.30 “Regulatory Authority” means any US or foreign governmental department, body, commission, board, bureau, agency or instrumentality with applicable regulatory jurisdiction.

2.31	“Reports” shall have the meaning set forth in Article V.

2.32 “Signature Date” means the date that this Agreement is last executed by Licensor’s Director.

2.33 “Sublicensee” shall mean a Person who obtains a sublicense under and pursuant to Article VI of this Agreement. Licensee shall initially and continuously identify, designate and update its relationship with each Sublicensee on Schedule 2.2 (Affiliates & Sublicensees) attached hereto and made a material part hereof, as amended or supplemented from time to time after notice and with approval of Licensor as contemplated hereunder.

2.34 “termination” and cognate words, such as “term” and “terminate,” shall have the meanings set forth in Article XI.

2.35 “Unaffiliated Person(s)” means any Person and shall include without limitation, an End-User or the joint venture partner, company or other entity that also has non-controlling outstanding equity securities of Licensee, an Affiliate or Sublicensee or has a non-controlling interest in the net assets or profits of Licensee, an Affiliate or Sublicensee.

2.36	“USFDA” means the U.S. Food and Drug Administration.

2.37	“USPTO” means the U.S. Patent and Trademark Office.

2.38 “Valid Claim” means: 1) a claim of an issued, unexpired patent included within the Licensed Patent Technology which either has not been (a) held unenforceable or invalid by a court or other governmental agency of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, or (b) admitted to be invalid or unenforceable through reissue, disclaimer or otherwise; or 2) a claim in a patent application within the Licensed Patent Technology.

ARTICLE III

LICENSE GRANT

3.1 In consideration of the payment of all License Fees and subject to full compliance with the terms and conditions of this Agreement by Licensee, Licensor grants to Licensee an exclusive license under the Licensed Patent Technology, with the right to grant and authorize sublicenses, to develop, to make, have made, import, use, have used, offer for sale, have sold and sell Licensed Products throughout the Licensed Territory in the Licensed Field of Use for the term of this Agreement and for the purpose stated in Article I. Licensee shall have the right to extend this license to any Affiliate of its choice, provided that each such extension properly references and is made subordinate to this Agreement, including those rights retained by Licensor hereunder, subject to and consistent with the relevant provisions hereof that apply to sublicenses, and the approval requirements of the United States Code, Title 35, Part II, Chapter 18, Section 209 (as amended) and U.S. Presidential Executive Order No. 12591.

3.2 No right or license is granted or implied to Licensee or to any Affiliate, Sublicensee or Person claiming through or under Licensee respecting any licensed patent or licensed patent application other than that specifically identified herein as the Licensed Patent Technology and the corresponding Licensed Field of Use. Nothing herein shall be construed as granting Licensee, by implication, estoppel or otherwise, any license or other right under or respecting any unlicensed Intellectual Property Rights of Licensor, except for those rights expressly granted under the Licensed Patent Technology and the corresponding Licensed Field of Use. Licensor specifically retains all residual rights and interests in and to the Licensed Patent Technology and its unlicensed Intellectual Property Rights and neither Licensee, its Affiliates or Sublicensees shall act in a manner that would or could impair or conflict either with the residual rights and interests of Licensor or the grant afforded to Licensee hereunder.

3.3 In full compliance and accordance with the FTTA, Licensee grants to Licensor a royalty-free, nonexclusive, worldwide license to practice and have practiced on behalf of the Government, and on behalf of any foreign government or international organization pursuant to any existing or future treaty or agreement with the Government, any patented invention made by Licensee, its Affiliates or Sublicensees pursuant to the terms of this Agreement for the term set forth in Article XI of this Agreement.

ARTICLE IV

LICENSE FEES: ROYALTIES AND PAYMENT OF OTHER INCOME

4.1	Licensee shall make payment and insure payment in full is made of all royalties and fees due and owing to Licensor as required under this Article IV (collectively hereinafter the “License Fee(s)”) and specifically described on Schedule 4.1 – License Fee(s) hereto.

4.2

No Licensee Fee shall be payable to Licensor under this Article IV solely with respect to Licensed Products distributed to third parties without consideration on a limited, restricted basis for use in research and/or development or as promotional samples. Licensee shall maintain and cause to be maintained records of all such activity with third parties, to be made available to Licensor upon request.

4.3

License Fees shall be payable on Net Sales of Licensed Product (the manufacture, use or sale of which is covered by a Valid Claim) on a country-by-country and Licensed-Product-by-Licensed-Product basis until: (i) the expiration of the last-to-expire patent included in the Licensed Patent Technology (including any extensions granted under the Patent Term Restoration Act or any other statute (as amended) covering each and every such Licensed Product in each and every such country; or (ii) if no such patent has issued in such country in which a patent application is pending, until the seventh anniversary of the first commercial sale of a Licensed Product in such country. No multiple royalty shall be payable on a Licensed Product because the manufacture, use or sale of such Licensed Product is covered by more than one patent or patent application in the Licensed Patent Technology.

4.4

The parties recognize that other patents covering the Licensed Patent Technology or Licensed Product may exist Licensee shall receive a credit against the royalty on Net Sales otherwise owed or owing to Licensor hereunder for royalties or equivalent fees paid by Licensee to third parties as such pertain to the Licensed Product. Any such credit shall not exceed [**] of

the royalties or equivalent fees actually paid by Licensee to seek a license under any other patents and/or other technology from an Unaffiliated Person in an arms length transaction in order to practice the rights and licenses granted by Licensor to Licensee hereunder and/or to avoid infringement during such exercise in any particular country, provided that in consultation with Licensor any such infringement determination is made by: (a) a competent court with personal and subject matter jurisdiction, (b) a mutually acceptable independent counsel regarding such practice and/or infringement, or (c) mutual agreement of the parties hereto.

4.5

Payments under this Article IV shall be made in United States dollars and paid by check to “DFAS ROCK ISLAND.” On a statement accompanying the check, it MUST be noted that the payment is for royalties or licensing fees, and each of the patent/patent applications and United States Department of Army log number(s) shall be listed and specifically referenced. All [D3] checks for payments under this Article IV should be mailed to DFAS – ROCK ISLAND OPLOC, ATTN: DFAS-R1-FD, Building 68, Rock Island, IL 61299-8300, with copies to the Licensor’s Representative at Office of Research and Technology Applications, U.S. Army Medical Research and Materiel Command, Staff Judge Advocate, (MRMC-JA), 504 Scott Street, Fort Detrick, Maryland 21702-5012, ATTN: USAMRMC ORTA. All checks and bank drafts shall be good funds drawn on United States banks.

4.6

For purposes of converting currencies other than U.S. Dollars to U.S. Dollars, Licensee shall use the average of the current exchange rate as reported in The Wall Street Journal under the column headed “Currency Trading” and subtitled “Exchange Rates” for the last business day of each month in which License Fees were earned for the applicable reporting period; provided, however, that if such rate is not so published, then such conversion rate shall be the average of the selling rate for such currency, as published by a leading New York City bank chosen by Licensee and reasonably acceptable to Licensor, on the last business of each month in which License Fees were earned for the applicable reporting period. Any and all loss of exchange, value, taxes or other expenses incurred in the transfer or conversion of other currency to U.S. Dollars shall be paid entirely by Licensee.

4.7

In the event that Licensee is unable, as a result of any legal or government restrictions, to remit License Fees or any other payments due hereunder from any country in the Licensed Territory in respect of sales in that country, Licensee shall deposit the appropriate License Fees and such other payments in an account in a bank in such country agreed to by Licensor, such agreement not to be unreasonably withheld. For as long as such restriction applies, Licensee shall be relieved of any further payment obligations to Licensor in respect of such Licenses Fees and such other payments, except that of reporting to Licensor under Article V concerning the amount of License Fees and such other payments payable and so deposited. Licensee shall continuously use commercially reasonable efforts to cooperate with Licensor in Licensor’s efforts to collect such License Fees and such other payments from such bank account.

4.8

Except as otherwise provided for hereunder, Licensee shall pay License Fees accrued according to Article IV and any other outstanding payments then due and payable hereunder, not later than 45 days after each calendar half year ending June 30^th and December 31^st. Licensee shall submit with its payment the written report required in Article V. If no License Fees are due, the report shall so state. Sales shall be deemed made, for purposes of this Section, when billed out, except that upon any termination of this Agreement, all shipments made on or

prior thereto shall be considered as sold (and therefore subject to License Fees or payments hereunder).

4.9	Licensee shall pay within 45 days from any termination of this Agreement License Fees and any other amounts due Licensor hereunder accrued or accruable for payment at the time of any such termination.

4.10	License Fees and any other payments due hereunder not received by Licensor by the due dates shall be subject to interest charges computed at [**] per annum.

ARTICLE V

REPORTS AND RECORDS

5.1 Licensee agrees to keep records showing the gross sales, Net Sales or other disposition of Licensed Products sold or otherwise disposed of under the license appropriate to determine the amount of License Fees and other payments due Licensor hereunder. Such records, including, without limitation, those of its Affiliates and Sublicensees, shall be retained for a period of five (5) years following the end of the calendar year to which such records pertain, and shall be treated and maintained as Confidential Information of Licensee. Such records should be in sufficient detail and clearly organized to enable the License Fees and any other amounts payable hereunder by Licensee to be determined, and Licensee further agrees to afford Licensor’s designated auditor or certified public accountant access, subject to the conditions set forth below in this Article V, to examine any and all relevant books and records of Licensee directly pertaining to Net Sales of the Licensed Product and License Fees owed and, where appropriate, those of its Affiliate(s) and Sublicensees, as may be necessary to make such determination. Upon thirty (30) days prior written notice, and not more often than once a year, Licensee shall make such records available for examination during normal business hours for the sole purpose of verifying the accuracy of Licensee’s payments and compliance with this Agreement for any period within the most recently completed five (5) calendar years during the term of this Agreement for five (5) years after the expiration or termination of this Agreement. If an auditor or certified public accountant is appointed by Licensor to conduct such an examination, Licensor shall bind such auditor or certified public accountant to an agreement not to disclose or use Licensee’s confidential or proprietary information except for verifying the amounts payable to Licensor pursuant to this Agreement. Licensor shall pay all audit expenses and costs except that Licensee shall assume and pay any and all audit expenses and costs incurred in the event any underpayment is reported which equals or exceeds [**] of the License Fees or other payments due Licensor hereunder. The parties agree to adhere to the rules and procedures established under the Administrative Dispute Resolution Act (5 USC Section 571, as amended) to resolve any dispute arising under this Section.

5.2 During the term of this Agreement, Licensee shall provide written annual progress reports (the “Point of Practical Application Reports”) not later than 45 days after the calendar year ending December 31^st, detailing its efforts, and the efforts of all Affiliate(s) and Sublicensees, to bring the inventions licensed under this Agreement to the Point of Practical Application, together with any additional information reasonably requested by Licensor or as contemplated and required under the Development Plan (the “Additional Information”). The Point of Practical Application Reports and any Additional Information shall contain reasonably

sufficient information to substantiate that Licensee is in full compliance with the terms of this Agreement and that the Development Plan is being executed. No such annual progress Point of Practical Application Reports shall be required with respect to any particular Licensed Product after notification of the first commercial sale of such Licensed Product, unless otherwise requested by Licensor.

5.3 Concurrently with each payment of amounts due and owing Licensor under this Agreement, Licensee shall also submit a true, accurate and complete written reports (collectively, the “Reports”) setting forth for the preceding six (6) month reporting period (a) the quantity of Licensed Products made, used, sold or otherwise disposed of by Licensee and its Affiliate(s) and Sublicensees, (b) the gross and Net Sales calculations thereof, and (c) a true, accurate and complete calculation of the amounts due to Licensor under this Agreement for each such period. If no License Fees or other payments are due Licensor for any reporting period, the Reports shall so state.

ARTICLE VI

SUBLICENSING RIGHTS

6.1 Licensee may grant sublicenses under the Licensed Patent Technology during the term of this Agreement to make, have made, import, use, have used, offer for sale and sell Licensed Products in the Licensed Territory. Each and every Sublicensee relationship shall be evidenced by a written agreement and made subject to Licensor’s approval (as required by 37 CFR 404.5(b)(4)), and each and every sublicense shall by proper reference be made subject and subordinate to this Agreement, including those rights retained by Licensor hereunder, consistent with the relevant provisions hereof that apply to sublicenses. A copy of any and all sublicenses shall be furnished to Licensor’s Representative promptly after its execution.

6.2 Modification or termination by Licensor under Article XI of any of the provisions of this Agreement shall modify or terminate all sublicenses, respectively, provided that any Sublicensee may elect to continue its sublicense by advising Licensor in writing, within 45 days of the Sublicensee’s receipt of written notice of such termination, of its election, and of its agreement to assume in respect to Licensor all the obligations (including obligations for payment) contained in its sublicensing agreement with Licensee. Any sublicense granted by Licensee shall contain corresponding provisions to those of this Article VI respecting conversion and termination and the conditions of continuance of sublicenses.

6.3 Licensee shall not grant or exercise any rights, which are inconsistent with the rights and obligations of Licensee or act in conflict with the residual rights of Licensor hereunder. Any Sublicensee agreement shall include an audit right by Licensor of the same scope as provided in Article V with respect to Licensee.

ARTICLE VII

LICENSEE PERFORMANCE

7.1 Throughout the term Licensee shall perform and shall cause its Affiliates and Sublicensees at all times to perform all of their respective duties and obligations as required

hereunder and under the Development Plan and Licensee shall expend and shall cause its Affiliates and Sublicensees where and to the extent appropriate to expend reasonable efforts and resources to carry out the development and marketing of the inventions, described and claimed in the Licensed Patent Technology.

7.2 After bringing the inventions, described and claimed in the Licensed Patent Technology, to the Point of Practical Application in the Licensed Territory, Licensee agrees and shall cause its Affiliates and Sublicensees to agree to keep Licensed Products available to the public during the term of this Agreement. Licensee shall promptly report discontinuance of the making of the benefits of the inventions reasonably accessible to the public.

7.3 A failure by Licensee or its Affiliate(s) and Sublicensees to comply with the terms of this Article VII or this Agreement shall be cause for modification or termination of this Agreement in accordance with the provisions of Article XI below.

ARTICLE VIII

MARKINGS

8.1 Licensee and its Affiliate(s) and Sublicensees, shall identify and cause to be identified, within a reasonable period of time, Licensed Products with the marking “Licensed Under U.S. Patent (number)” or “U.S. Patent Pending” as permitted or required by statute or identify Licensed Products as patented in any promotional literature used.

8.2 The name of the Government employee inventor(s), the name of the agency or department of the Government or any adaptation of the above shall not be used in any promotional activity without prior written approval from Licensor.

ARTICLE IX

PATENT ENFORCEMENT AND PROSECUTION

9.1 Licensor and Licensee shall notify each other promptly in writing of any infringement of the Licensed Patent Technology that becomes known to either of them. Licensee shall notify Licensor promptly of any action taken in accordance with this Article IX to prevent or eliminate such infringement.

9.2 Licensee is empowered pursuant to this Agreement and the provisions of the United States Code, Title 35, Parts II and III, Chapter 18, Section 207, and Chapter 29, Section 281-297, to (a) bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably Valid Claims in the Licensed Patent Technology hereunder, to enjoin infringement and to collect for its use and distribution as noted in Section 9.4 below, damages, profits and awards of whatever nature recoverable for such infringement; and (b) subject to approval by Licensor (not to be unreasonably withheld), settle any claim or suit for infringement of the Licensed Patent Technology, provided, however, that Licensor and the appropriate Government authorities shall have a continuing right to intervene in such suit. Licensee shall obtain the prior written consent of Licensor before pursuing any litigation. Licensee shall take no action to compel the Government either to initiate or to join in any such suit for patent infringement unless

such action is ultimately necessary to avoid a dismissal of such suit by Licensee, in which case Government shall consent to be joined.

9.3 If the Government is be made a party to any such suit by the motion or any other action of Licensee, Licensee shall reimburse the Government for any costs, expenses or fees which the Government incurs as a result of such motion or other action, including any and all costs incurred by the Government in justifiably opposing any such joinder motion. Upon payment by Licensee of all costs incurred by the Government as a result of Licensee’s joinder motion or other action, any such action taken by Licensee shall not be considered a default in the performance of any material obligation under this Agreement. In any event, Licensee agrees to keep Licensor completely apprised of the legal strategies, status and progress of any such litigation and to consider the potential effects of the litigation on the public health in deciding whether to pursue litigation of any kind.

9.4 Except as otherwise provided in this Article, any and all fees, costs and expenses incurred, including, without limitation, attorney’s fees, court costs and disbursements in connection with any action taken under this Article IX shall be paid by Licensee. Up to [**] of such fees, costs and expenses may be credited against the royalty on Net Sales otherwise payable to Licensor in the country in which such a suit is filed under this Agreement. In the event that [**] of such fees, costs and expenses exceed the amounts withheld by Licensee in any calendar year, the excess may be carried over as a credit on the same basis into succeeding calendar years. Any recovery by Licensee, through court, judgment or settlement, shall be applied equally to reimburse Licensor for such amounts withheld as a credit against litigation expenses and to reimburse Licensee for its litigation expenses. Any remaining recoveries by Licensee after expenses shall be shared and distributed equally between the Licensor and Licensee.

9.5 Licensor shall cooperate fully with Licensee in connection with any action under this Article IX. Licensor agrees to promptly provide reasonable access to all necessary documents and to render reasonable assistance in response to a request by Licensee.

9.6 Licensor shall have the right, at its own expense, to sue for infringement of the Licensed Patent Technology in the event that Licensee elects not to do so, after having received written notice from Licensee. In such an event Licensor shall retain the full amount of any and all recoveries and reserves the right to terminate the license granted to Licensee and/or this Agreement Article XI.

9.7 In the event that a declaratory judgment action alleging invalidity or infringement of any claim of the Licensed Patent Technology shall be brought against Licensee or Licensor or raised by way of counterclaim or affirmative defense in an infringement suit brought by Licensee, Licensee is empowered pursuant to this Agreement and the provisions of the United States Code, Title 35, Parts II and III, Chapter 18, Section 207, and Chapter 29, Sections 281-297, or other applicable statutes to: (1) defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the Licensed Patent Technology hereunder; (2) in any such suit, ultimately to enjoin infringement and to collect for its use and distribution as noted in Section 9.4 above, damages, profits and awards of whatever nature recoverable for such infringement, and (3) subject to approval by Licensor, not to be unreasonably withheld, settle any claim or suit for declaratory infringement involving the Licensed Patent Technology; provided, however, that Licensor and appropriate Government authorities shall have a continuing

right to intervene in such suit. Licensee shall take no action to compel the Government either to join in any such declaratory judgment action unless such action is reasonably necessary to avoid prejudice to Licensee. If the Government is to be made a party to any such suit by the motion or any other action of Licensee, Licensee shall reimburse the Government for any costs, expenses or fees which the Government incurs as a result of such motion or other action, including any and all costs incurred by the Government in justifiably opposing any such motion or other action. Upon payment by Licensee of all costs incurred by the Government as a result of any such motion or other action, any such action taken by Licensee shall not be considered a default in the performance of any material obligation under this Agreement. If Licensee elects not to defend against such declaratory judgment action, it shall notify Licensor in writing, and at such time, Licensor, at its option, may do so at its own expense. In any event, Licensee agrees to keep Licensor completely apprised of the legal strategies, status and progress of any such litigation and to consider the potential effects of the litigation on the public health in deciding what steps to take or not to take throughout the course of such proceedings.

9.8 From and after the Signature Date, Licensee shall take responsibility for the preparation, filing, prosecution and maintenance of any and all patent applications and patents included in the Licensed Patent Technology within the Licensed Field of Use, in addition to the reimbursement and expense obligations required under Article IV above. Licensee agrees to retain a patent law firm and/or patent agents reasonably satisfactory to Licensor to handle all preparation, filing, prosecution and maintenance of the patent applications and patents within the Licensed Patent Technology. Licensee and its counsel shall furnish to Licensor copies of all documents, or all portions thereof, relevant to any such preparation, filing, prosecution or maintenance, including all correspondence between Licensee’s counsel and the USPTO or a Regulatory Authority with applicable jurisdiction. Licensee shall pay all fees and expenses incurred after the Signature Date for the preparation, filing, prosecution and maintenance of the Licensed Patent Technology that include one or more claims within the Licensed Field of Use. Licensor shall cooperate fully in the preparation, filing, prosecution and maintenance of the Licensed Patent Technology and of all patents and patent applications licensed to Licensee hereunder, executing all papers and instruments, including, without limitation, appropriate powers of attorney and such papers and instruments as may be useful or necessary so as to enable Licensee to apply for, to prosecute and to maintain the Licensed Patent Technology in the United States, the EU or in any other nation, country or comparable political jurisdiction. Each party shall provide to the other prompt notice as to all matters which come to its attention and which may affect the preparation, filing, prosecution or maintenance of any of the Licensed Patent Technology. In the event Licensor believes that Licensee is failing to diligently file, prosecute and maintain the Licensed Patent Technology, it shall so notify Licensee in writing. Licensee shall have sixty (60) days to respond to Licensor demonstrating its commercially reasonable efforts in such filing, prosecution and maintenance. If Licensee fails to demonstrate such efforts within such time, Licensee shall, upon request of Licensor, grant to Licensor a form of power of attorney for the sole purpose of filing, prosecution and maintaining those patent applications and/or patents in the Licensed Patent Technology for which Licensee has failed to demonstrate diligence.

ARTICLE X

RESERVATION OF RIGHTS

10.1 The license granted in Article III of this Agreement shall be subject to the irrevocable, nonexclusive, nontransferable, royalty-free right of the Government to practice the inventions, described and claimed in the Licensed Patent Technology or any Improvements thereof, on behalf of the United States and on behalf of any foreign government or international organization pursuant to any existing or future treaty or agreement with the United States, for research and other Government purposes, either alone or with one or more third parties, provided that any third party shall have involvement only to assist the Government for the limited purpose set forth above. In the exercise of such license, the Government shall not publicly disclose trade secrets or commercial or financial information that is privileged or confidential within the meaning of United States Code, Title 5, Part I, Chapter 5, Subchapter II, Section 552(b)(as amended).

10.2 Licensor, pursuant to the United States Code, Title 35, Part II, Chapter 18, Section 203 (as amended), and the underlying federal regulations, reserves the right to require the Licensee and its Affiliate(s) and Sublicensees to grant a nonexclusive, partially exclusive, or exclusive license in any field of use to a responsible applicant or applicants, upon terms that are reasonable under the circumstances, either voluntarily or involuntarily as permitted under applicable law, when necessary to fulfill public health or safety needs. A determination pursuant to this section shall not be subject to the Contract Disputes Act (41 U.S.C. Sec. 601 et seq.)(as amended).

ARTICLE XI

TERM AND TERMINATION

11.1 The term of this Agreement shall commence on the Signature Date, and unless terminated in accordance with this Article XI, shall continue in effect until the later of (a) the expiration date of the last to expire patent in the Licensed Patent Technology; or (b) the date of the last abandonment of a patent application in the Licensed Patent Technology.

11.2 The Licensor shall have the right to modify or terminate this Agreement and/or the underlying license, in whole or in part, upon the occurrence of any one of the following events (each an “Event of Default”):

(a) Licensee or any of its Affiliate(s) or Sublicensees fails to perform and meet the obligations set forth in Article VII above, and Licensee cannot otherwise demonstrate to Licensor’s reasonable satisfaction that Licensee or any of its Affiliate(s) or Sublicensees has taken, or can be expected to take within a reasonable time, effective steps to so perform and meet the obligations set forth in Article VII above.

(b) The Licensor determines that such action is necessary to meet requirements for public use specified by Government regulations issued after the date of this Agreement and such requirements are not reasonably satisfied by the Licensee;

(c) The Licensee makes a misrepresentation or has made a materially false statement of, or omitted, a material fact in the license application, the Development Plan, or in any Point of Practical Application Report, Additional Information, Report or other information provided to Licensor as required by this Agreement or in the Development Plan;

(d) The Licensee or its Affiliate(s) or a Sublicensee commits a material breach of this Agreement as determined by Licensor;

(e) Any cause of action or claim of Licensor accrued or to accrue, because of any breach or default by Licensee or its Affiliate(s) and Sublicensees under this Agreement.

11.5 In the event of termination of this Agreement and/or conversion and/or modification of the License granted hereunder, any Sublicensee agreement of record granted pursuant to this Agreement may, at such Sublicensee’s option, be converted to a license directly between Sublicensee and Licensor in accordance with the provisions of Article VI.

11.6 Licensee shall have the right to terminate this Agreement without cause at any time effective ninety (90) days after written notice as to any patent application or patent within the Licensed Patent Technology. A termination without cause by Licensee may, at the option of Licensor, give rise to an additional termination fee due on demand to cover administrative and related costs and expenses not to exceed [**], in addition to any and all monies otherwise due and owing hereunder. Licensee shall also have the right to terminate this Agreement in the event Licensor materially breaches the terms and conditions of this Agreement and fails to correct such material breach within ninety (90) days after receipt of written notice from Licensee specifying the breach alleged to have occurred, unless such breach is susceptible to cure and remedied within a reasonable period of time before or after the ninety (90) day period.

11.7 In the event of any termination of this Agreement under this Article XI (other than upon expiration of the term specified in this Article XI), Licensee and its Affiliates(s) and Sublicensees shall be permitted, for a period of thirty (30) days or longer with the approval of Licensor, to complete the sale of its existing inventory of Licensed Products and Licensor shall be entitled to the payment of License Fees and any other amounts due Licensor hereunder and as provided in Articles IV, V and IX with respect thereto.

ARTICLE XII

ACKNOWLEDGEMENTS AND REPRESENTATIONS

12.1 Subject to Section 14.3, Licensor represents and warrants that: (a) it is the owner of all right, title and interest in the Licensed Patent Technology; (b) it has the right to grant the rights and licenses granted herein, and the Licensed Patent Technology is free and clear of any lien, encumbrance, security interest or restriction on license; (c) it has not previously granted, and will not grant during the term of this Agreement any right, license, or interest in and to the Licensed Patent Technology, or any portion thereof, inconsistent with the license granted to Licensee herein; (d) to its knowledge, no other intellectual property owned by Licensor is necessary to practice the Licensed Patent Technology; and (e) to its knowledge, there are no threatened or pending actions, suits, investigations, claims or proceedings in any way relating to the Licensed Patent Technology.

12.2 Licensee represents and warrants that: (a) it is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware; (b) the execution, delivery and performance of this Agreement and related materials have been duly authorized by all necessary corporate action on the part of Licensee; (c) it intends and shall use the Licensed Patent Technology solely as contemplated hereunder and shall be primarily liable and responsible for the use of the Licensed Patent Technology by all Affiliates and Sublicensees; (d) it shall take any and all necessary and reasonable precautions to comply with the terms and conditions of this Agreement; and (e) it shall operate and conduct its affairs in compliance with all federal, state, and local laws which apply to its performance under this Agreement and, as a result, shall apply for and maintain any necessary licenses required by such laws and immediately notify the Licensor in the event any application is denied, or in any way terminated or limited.

ARTICLE XIII

DEVELOPMENT PLAN

Concurrent with the execution of this Agreement, the Development Plan prepared and attached by Licensee shall be in effect and relied on by Licensor as an inducement to enter into this Agreement. The Development Plan as may be amended from time to time is attached as Schedule 2.7 (Development Plan) hereto.

ARTICLE XIV

GENERAL

14.1 Neither Licensee, nor its successors or assigns, shall, by operation of law or otherwise, transfer or assign this Agreement or encumber the Licensed Patent Technology, without the prior written consent of Licensor in each instance. If any part or all of the shares of stock or equivalent interests of Licensee, or the shares of stock or equivalent interests of any corporation or entity owning shares of Licensee’s stock or equivalent interests representing effective voting control of Licensee or its business, shall be transferred by sale, assignment, conveyance, operation of law or other disposition so as to result in a change in the present effective voting control of Licensee or its business, or of such other corporation or entity, by the individual or individuals owning a majority of such shares of stock or equivalent interests, then such transfer shall be deemed to be an assignment or transfer of this Agreement to which Licensor’s consent must be given; provided, however, that (a) an assignment incident to a merger or consolidation of Licensee into or with an entity having net assets equal to or greater than the net assets of Licensee as of the date of such transfer, or (b) an assignment or transfer to an entity purchasing the entire business of Licensee or that part of the business to which this Agreement relates, may be made without Licensor’s consent (subject to the last sentence below), if such entity shall assume all of the obligations of Licensee under this Agreement pursuant to an instrument reasonably acceptable to Licensor. Notwithstanding any assignment or transfer of this Agreement (whether or not Licensor’s consent is required), Licensee shall remain responsible jointly and severally, with any assignee or transferee for payment of any and all obligations and the performance of all of the covenants, conditions and agreements of Licensee hereunder. In no event shall Licensee, its successors or assigns transfer or assign this Agreement to a party not a

citizen, resident or other entity incorporated or arranged under the laws of a state or territory of the United States of America without the express written approval of Licensor.

14.2 This Agreement does not confer any immunity from or defenses under the antitrust laws, the laws and regulations pertaining to or administered by the USFDA, or the export laws nor does it confer immunity from a charge of patent misuse. Furthermore, neither Licensee’s, nor its Affiliates’ or Sublicensees’ acquisition and exercise of rights hereunder shall be immunized from the operation of any state or Federal law by reason of the source of the grant. This Agreement does not constitute an endorsement by Licensor of any Licensed Products and neither Licensee, nor its Affiliate(s) or Sublicensees shall not state or imply in any medium that such endorsement exists as the result of this Agreement.

14.3 Licensor makes no warranty, express or implied, or any representations regarding the patentability, validity or scope of the Licensed Patent Technology or that Licensed Patent Technology may be exploited without infringing patents of third parties.

14.4 Notwithstanding anything to the contrary set forth herein, Licensee and its Affiliate(s) and Sublicensees agree that Licensed Products will be manufactured substantially in the United States of America and its jurisdictional territories in compliance with all applicable laws including, without limitation, the United States Code, Title 35, Part II, Chapter 18, Section 209 (as amended) and U.S. Presidential Executive Order No. 12591 and that any permitted transfer of technology to foreign entities shall strictly comply with the Export Administration Regulations, 15 CFR Sections 730-774 (as amended). Licensee and its Affiliates further agree and understand that a failure to strictly comply with such laws and regulations may result in criminal liability under United States laws.

14.5 Solely for the informal administrative process of resolving disputes extra-judicially (and not to foreclose to either party any other remedy under equity or law) the decision of Licensor’s Representative on any requirement, dispute, interpretation, modification or termination of this Agreement shall be reduced to writing and a copy mailed or otherwise furnished to Licensee. Such decision shall be deemed a final exhaustion of administrative remedies, provided that Licensee may, within thirty (30) days of receiving notice of such decision, submit a written appeal through Licensor’s Representative and the Intellectual Property Counsel of the Army to the Judge Advocate General, Department of the Army, Washington, DC 20310-2207, which appeal shall set forth in detail the decision being appealed and the basis of the appeal and may include appropriate supporting materials. Implementation of such decision shall be stayed pending a final resolution of such appeal. Pending such final resolution and therefore the exhaustion of the administrative remedy process, each party shall proceed diligently with the performance of its obligations under this Agreement, provided that upon such final resolution, either party may then seek remedy through the judicial process.

14.6 Except for complete nondisclosure of certain Intellectual Property Rights specifically designated by Licensor or as otherwise expressly provided herein, the parties agree that, during the term of this Agreement and for ten (10) years thereafter, the receiving party shall keep completely confidential and shall not publish or otherwise disclose and shall not use for any purpose except for the purposes contemplated by this Agreement any Confidential Information furnished to it by the disclosing party hereto pursuant to this Agreement. Licensee may use or disclose information disclosed to it by Licensor to the extent such disclosure is reasonably

necessary, in filing or prosecuting patent applications, prosecuting or defending litigation, complying with applicable governmental laws and regulations or otherwise submitting information to tax or governmental authorities, conducting clinical trials, acquiring potential investors, or making a permitted sublicense or otherwise exercising its rights hereunder, provided that if Licensee is required to make any such disclosure of Licensor’s Confidential Information, other than pursuant to a confidentiality agreement acceptable to Licensor, it will give reasonable notice to Licensor of such disclosure and, save to the extent inappropriate in the case of patent applications, will use its commercially reasonable efforts to secure confidential treatment of such information prior to and after its disclosure (whether through protective orders or otherwise). Licensee agrees to keep records of confidentiality agreements between itself and third parties in accordance with the treatment of Confidential Information given in Article V. Licensor may disclose Licensee’s Confidential Information to governmental authorities as may be required by law, provided that it shall give Licensee notice, and shall take commercially reasonable efforts to secure confidential treatment of such information prior to and after its disclosure (whether through protective orders or otherwise). This Section 14.5 shall survive any termination or expiration of this Agreement.

14.7 The parties understand that from time to time, Licensor may desire to publish or publicly disclose certain summary information regarding this Agreement. In such an event, Licensor shall provide Licensee with a copy of any proposed publication at least thirty (30) days in advance for its review and comment. Following Licensee’s review and due consideration of Licensee’s comments, as well as the deletion of Licensee’s Confidential Information, Licensor shall be free to publish such information.

14.8 The parties shall notify each other of any changes in name, address, or business status, and any notice or report required to be given under the provisions of this Agreement shall be considered duly given if mailed by first class mail, potage prepaid or by an express/overnight delivery service provided by a commercial carrier, and addressed as follows:

(a)

If to Licensor:

U.S. Army Medical Research and Materiel Command

Staff Judge Advocate (MCMR-JA)

504 Scott Street

Fort Detrick, Maryland 21702-5012

Attn: USAMRMC ORTA

(b)

If to Licensee:

VaxGen, Inc

1000 Marina Boulevard

Brisbane, California 94005-1841

Attn: Piers Whitehead

Notice shall be considered timely if such notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier.

14.9 This Agreement shall be governed by and construed in accordance with the federal laws of the United States of America as interpreted and applied by the federal courts in the District of Columbia, United States of America, without giving effect to principles of conflicts of laws. Each of the parties hereby irrevocably submits to the jurisdiction of any Federal court sitting in

the District of Columbia over any action or proceeding arising out of or relating to this Agreement and each hereby waives the defense of an inconvenient forum for the maintenance of such action.

14.10 This Agreement, together with all schedules and attachments, constitutes the entire understanding between the parties and neither party shall be obligated by any condition or representation other than those expressly stated herein or as may be subsequently agreed to by the parties hereto in writing.

14.11 All prior reviews and approvals required by regulations or law have been obtained by the Licensor prior to the execution of this Agreement. The Licensor’s Director executing this Agreement has the requisite authority to do so.

14.12 Failure of any party to enforce any term, covenant, or condition herein contained shall not be deemed to be a waiver of such term, covenant, or condition herein contained.

14.13 Neither party shall be in default hereunder by reason of its delay in the performance of, or failure to perform, any of its obligations hereunder, other than Licensee’s obligations to make payments to Licensor in accordance with the terms of this Agreement, if such delay is caused by war, strikes, acts of God or the public enemy, riots, without the fault or negligence of the other party. During the pendency of such intervening event, each of the parties shall take all reasonable steps to furnish the services required hereunder by other means, and, in any event shall, upon termination of such intervening event, forthwith resume obligations under this Agreement.

14.14 The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of law, such termination shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement.

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be executed in triplicate originals by its duly authorized officers or representatives on the day and year set forth below.

FOR LICENSEE:

VaxGen, Inc.

BY:

__/s/ P. Whitehead_______________

NAME: Piers Whitehead

TITLE: VP Corporate and Business Development

DATED: _10.7.03________________________

WITNESS: __/s/ Lance Gordon__________________

DATED: _10.7.03__________________________

FOR LICENSOR:

U.S. Army Medical Research Institute of Infectious Diseases

BY:

__/s/ James R. Swearengen___________________

for

NAME: Erik A. Henchal, Colonel, U.S. Army

TITLE: Commander

DATED: ___07 Oct 03____________________

WITNESS: _/s/ Maryam Azarion________

DATED: __07 Oct 03__________________

Schedle 2.2 (Affiliates & Sublicensees)

None at the time of initial Execution.

Schedule 2.7 (Development Plan)

[**]

Schedule 2.17 – A (Existing Patents)

U.S. Patents

6,316,006, November 13, 2001, Asporogenic B, anthracis Expression System. Worsham, Friedlander, Ivins

6,387,665, May 14, 2002, Method of Making a Vaccine for Anthrax. Ivins, Worsham, Friedlander, Farchaus, Welkos

Schedule 2.17 – B (Additional Patents and Patent Applications)

I.	Additional Patents.

None

II.	Patent Applications.

None

III.	Ancillary Property Rights.

Schedule 4.1

LICENSE FEES: ROYALTIES AND PAYMENT OF OTHER INCOME

Licensee shall make payment and insure payment in full is made of all royalties and fees due and owing to Licensor under Article IV (collectively hereinafter the “License Fee(s)” described as follows:

(a)

Within 45 days after the Signature Date, Licensee shall pay to Licensor an execution fee of [**] dollars [**] no part of which shall be refunded for any reason.

(b)

Also within 45 days after the Signature Date, Licensee shall pay to Licensor a patent maintenance fee of [**] dollars [**]. Licensee shall pay a second patent maintenance fee, in the amount of [**] dollars [**], within 45 days of 31 March 2005, unless this Agreement is Terminated prior to that date.

(c)

Within 45 days of the first anniversary of the signature date, and on each anniversary thereafter whilst this agreement is in effect, Licensee shall pay to Licensor an anniversary fee of [**] dollars [**].

(d)

From and after the Signature Date, Licensee shall make certain milestone payments to Licensor corresponding to the product development cycle for the first Licensed Product under development for use in either the United States or in any sovereign state with regulatory powers (the “Regulatory Authority”). Licensee shall make such milestone payment to Licensor according to the following schedule:

(i)

Licensee shall pay to Licensor the sum of [**] dollars [**] due within 45 days of the successful conclusion of the first Phase I testing by Licensee, its Affiliates or any Sublicensee the Licensed Product. For purposes of this subsection, successful conclusion of Phase I testing shall mean that the USFDA or the Regulatory Authority with jurisdiction has approved the transition from Phase I to Phase II testing.

(ii)

Licensee shall pay to Licensor the sum of [**] dollars [**] due within 45 days of the successful conclusion of the first Phase II testing by Licensee, its Affiliates or any Sublicensee of the Licensed Product. For purposes of this subsection, successful conclusion of Phase II testing shall mean that the USFDA or the Regulatory Authority with jurisdiction has approved the transition from Phase II to Phase III testing.

(iii)

Licensee shall owe to Licensor the sum of [**] dollars [**] upon successful conclusion of the first Phase III testing by Licensee, its Affiliates or any Sublicensee of the Licensed Product. For purposes of this subsection, successful conclusion of Phase III testing shall mean that

an application for regulatory approval for the Licensed Product (e.g., NDA or BLA) has been filed with the USFDA.

(e)

Within 45 days of the Licensee, its Affiliates or Sublicensees obtaining marketing approval from the FDA for the Licensed Product, Licensee shall pay Licensor [**] dollars [**].

(f)

Licensee shall pay Licensor a royalty on the Net Sales of all Licensed Products the manufacture, use or sale of which is covered by a Valid Claim, sold or transferred to Unaffiliated Persons or otherwise disposed of within the Licensed Territory by Licensee, its Affiliates and Sublicensees. The royalty rate on Net Sales of Licensed Products to non-U.S. Government customers shall be [**] or provided under contract to any agency of the United States Government [**].